Bispecific ADC targeting ITGB4 and TROP2 (Genome & Company)

N/A

Report date: 2026/04/15 20:02:38

Base Information

Drug NameBispecific ADC targeting ITGB4 and TROP2 (Genome & Company)
Drug Alias Namethe variable region of sacituzumab with anti-ITGB4 antibody, GENA-120B17GENB-120
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-Integrin Subunit Beta 4Anti-Trop-2
TargetsIntegrin Subunit Beta 4Tumor-associated calcium signal transducer 2
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesGenome & Company
China Registration ClassN/A

Develop Information

Active CompaniesGenome & Company
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A